Bayer is transforming healthcare by integrating GenAI across various sectors, reducing time-consuming processes and enhancing patient outcomes.
Bayer is spearheading the integration of GenAI across healthcare, significantly improving efficiency in drug discovery, clinical trials, medical coding, and radiology. This integration speeds up processes and significantly improves patient care.
In drug discovery, Bayer’s use of GenAI to navigate its vast compound library speeds up the identification of potential treatments for conditions like heart failure. By enabling quicker and more accurate analysis of chemical interactions, GenAI helps streamline the development of essential medications.
For clinical trials, traditionally the most time-intensive phase of drug development, Bayer employs GenAI to optimize trial design and patient selection. Collaborations with top universities and hospitals allow for AI-assisted trials that enhance safety and efficiency, speed up drug evaluations, and reduce potential risks.
In medical coding, Bayer’s natural language processing application converts physician notes into standardized data with 96% accuracy. Since 2017, this automation has saved about 170,000 hours of manual work, accelerating clinical research and reducing overhead.
Lastly, in radiology, Bayer’s Calantic Digital Solutions uses AI to automate routine tasks, thereby enhancing diagnostic precision and expediting patient care. This system allows radiologists to focus more on direct patient interactions and complex cases, improving overall healthcare delivery.
Through strategic applications of GenAI, Bayer is setting new healthcare efficiency and patient care standards, promising faster and more effective treatment solutions worldwide.